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Muscarinic receptors are a functionally important family of G-pro-
tein–coupled receptors. Using a combination of rapid amplification
of 5 cDNA ends and reporter gene assays, we characterized the
5 untranslated region of the CHRM2 gene as expressed in human
airway smooth muscle (HASM) cells. A splice site is present 46 bp
upstream from the ATG start codon. Five exons with alternative
splicing patterns are present upstream of this splice site, separated
by introns ranging from 87 bp to  145 kb. There is evidence for
the gene being under the control of a TATA-less promoter with Sp1,
GATA, and activator protein-2 binding sites. Multiple transcription
start sites (TSSs) were identified. We identified a novel 0.5-kb hyper-
variable region located 648 bp upstream of the most 5 TSS, a
multiallelic (CA) tandem repeat 96 bp downstream of the most 5
TSS, and a common C→A SNP located 136 bp upstream of the most
5 TSS. Functional studies in primary HASM cells and the BEAS-2B
cell line demonstrated highest promoter activity to be upstream of
the most 3 TSS, with potential repressor elements operating in a
cell type–dependent manner, located upstream of the most 5 TSS.
We present functional data to show that the CA repeat may influ-
ence the transcription of the gene in HASM and BEAS-2B cells.
The human muscarinic M2 receptor is a functionally important
membrane-bound protein that is negatively coupled to adenylyl
cyclase and is widely expressed in a range of tissues, including
cardiac myocytes, prejunctional cholinergic nerve endings, and
smooth muscle. In the airways, M2 receptors are constitutively
expressed on airway smooth muscle (ASM) and, in contrast to
muscarinic M3 receptors, continue to be expressed during pri-
mary culture (1). Muscarinic M2 receptors play an important
role in the control of ASM cAMP regulation, being responsible
for acetylcholine-mediated inhibition of adenyl cyclase activity.
This action ameliorates in part the relaxant effect of agents such
as isoproterenol in the airways (2).
Despite the cloning of the human muscarinic M2 receptor
gene several years ago (3, 4) the elements important for tran-
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scriptional regulation of the gene in ASM have not so far been
identified. In recent years, knowledge of the regulatory regions
of the different muscarinic genes has been enhanced due to
studies in other species (rat M1 [5], chicken M2 [6], porcine M2
[3, 4], rat M4 [7]).
In the human genome, the promoter region has been identi-
fied for the M1 receptor subtype (5) and the M3 subtype (8). Zhou
and coworkers recently described a muscarinic M2 promoter
arrangement based on work performed on mRNA transcripts
obtained from human heart muscle and the human neuro-
blastoma cell line IMR-32 (ATCC No. CCL-127) (9). In the
majority of studies on different muscarinic receptor subtypes,
the promoter is spatially separated from the coding exon by at
least one noncoding exon and more than 4.4 kb of intronic
sequence. To date, the human muscarinic M3 5 untranslated
region (UTR) is reported to be the most complex. Findings by
Forsythe and colleagues show the existence of seven upstream
exons ranging from 99–298 bp and introns of lengths ranging
between 171 bp and  65.2 kb (8).
All the muscarinic gene regulatory regions studied to date
appear to be TATA-less promoters, containing consensus bind-
ing sites for a number of transcription factors reported to be
important in promoter activity (10). Consistent with being a
TATA-less promoter, transcription of the chick muscarinic M2
gene is initiated at 5 or more sites within a 146-bp segment
located 321 bp upstream from the 5-end of the 5UTR. These
sites are preferentially used in a cell-specific manner (6).
In this article we describe a series of studies in which the
upstream arrangement of the human muscarinic M2 receptor
gene was characterized and the putative promoter regions identi-
fied by studying mRNA transcripts obtained from primary cul-
tures of human ASM (HASM) cells. In addition, we define
novel polymorphic regions that have the potential to influence
transcriptional activity of the M2 receptor gene.
Materials and Methods
5RACE Procedure
Preparation of RNA. Primary cultures of HASM cells were prepared
from explants of trachealis muscle obtained from individuals without
respiratory disease within 12 h of death as previously described (11).
Following the establishment of a confluent monolayer of HASM cells
in a 75 cm2 flask, cells were harvested by trypsinisation and pelleted
by centrifugation, as previously described (11). Total RNA was then
extracted from the cells using the RNeasy Qiagen kit. RNA samples
were then DNase treated using DNase I (Gibco-BRL, Paisley, UK) to
eliminate potentially contaminating DNA.
5 Rapid amplification of cDNA ends. 5 rapid amplification of 5
cDNA ends (5RACE) of HASM cell cDNA was performed using the
GeneRacer system (Invitrogen Life Technologies, Paisley, UK) according
to the manufacturer’s recommended protocol. In contrast to conventional
5RACE, the GeneRacer system ensures that only mature capped
mRNA transcripts participate in the reaction. In brief, total RNA ex-
tracted from HASM cells was treated with calf intestinal phosphatase
(CIP) to dephosphorylate the 5 ends of truncated mRNA and non-
mRNA molecules and thereby inhibit their participation in downstream
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reactions. The dephosphorylated RNA was treated with tobacco acid
pyrophosphatase (TIP) to remove the 5 cap structure from mature full-
length mRNA, leaving a 5 phosphate group available. A manufacturer-
supplied RNA oligonucleotide (5-CGA CUG GAG CAC GAG GAC
ACU GAC AUG GAC UGA AGG AGU AGA AA-3) was ligated
to the decapped mRNA using T4 RNA ligase, thus providing a priming
site for later amplification procedures. First-strand cDNA synthesis was
performed using SuperScript II reverse transcriptase and a manufac-
turer-supplied oligo dT primer (5-GCT GTC AAC GAT ACG CTA
CGT AAC GGC ATG ACA GTG (T)18-3). Double-stranded cDNA
was subsequently prepared by amplifying the first strand product using
a reverse gene-specific primer (reverse GSP) designed to be within
the M2 receptor gene coding region, and the GeneRacer 5 primer
(homologous to the previously ligated RNA oligonucleotide). A second
nested polymerase chain reaction (PCR) was performed using a manu-
facturer-supplied 5 nested primer and a reverse nested gene-specific
primer (reverse nested GSP) (see Table 1 for primer details). This step
increased the product yield available for later cloning, and in addition
eliminated any potential nonspecific products of the first PCR. The
nested PCR products were gel-purified and cloned as described below.
The whole 5RACE procedure was performed twice using different
populations of HASM cells.
Cloning. The pCR4-TOPO vector (Invitrogen Life Technologies) was
used for TA cloning. The purified nested PCR product mixture was
ligated to pCR4-TOPO by incubation at 22C for 5 min in the presence
of 200 mM NaCl and 10 mM MgCl2. The ligation mixture was then used
to transform One Shot TOP10 chemically competent Escherichia coli
cells (Invitrogen Life Technologies) using heat shock for 30 s at 42C.
The cells were grown in SOC broth for 1 h at 37C, after which they
were plated onto Lennox Broth (LB) agar plates containing ampicillin
for selection of positive transformants, and incubated overnight at 37C.
Several colonies were subsequently picked and grown in selective LB
broth at 37C with shaking (250 rpm) overnight. Each broth (5 l) was
streaked out on a selective LB agar plate, and the plates were incubated
at 37C overnight. One colony was picked from each plate, and grown
in 5 ml selective LB broth at 37C with shaking (250 rpm) overnight.
Plasmid DNA extraction. Plasmid DNA was extracted from each
E. coli broth using Wizard Plus SV Minipreps DNA Purification System
(Promega Corporation, Madison, WI), using sterile deionized water to
elute the final product. An aliquot of each extract was restricted using
EcoR1 to excise the insert, and viewed on a 1% agarose gel. Successful
extracts were submitted for sequencing.
Sequencing. DNA dideoxy sequencing was performed using an ABI
377 Genetic Analyzer and the ABI Big Dye Terminator Ready Reaction
Mix (Applied Biosystems, Foster City, CA). Each clone was sequenced
in both directions using vector primers M13-forward and M13-reverse,
respectively.
Sequence data analysis. The data obtained from sequencing was
analyzed by comparing it to the NCBI human genome database, using
the Basic Local Alignment Search Tool available at http://www.ncbi.nlm.
nih.gov/BLAST/.
TABLE 1. Oligonucleotide primers used for 5RACE analysis
Primer Sequence
M2 RACE
GSP
(reverse) 5-GGT CTG GAG GTG GCG GTT GAC TT-3
GeneRacer 5
primer
(forward) 5-CGA CTG GAG CAC GAG GAC ACT GA-3
M2 RACE
nested GSP
(reverse) 5-GCC ACC AGG ACA ATA AAC ACC ACT TC-3
GeneRacer 5
nested
primer
(forward) 5-GGA CAC TGA CAT GGA CTG AAG GAG TA-3
The initial PCR was performed using the manufacturer-supplied GeneRacer 5
forward primer and our designed M2 RACE reverse gene-specific primer (GSP).
A second nested PCR was performed using the manufacturer-supplied GeneRacer
5 nested primer, and our designed M2 RACE nested GSP.
Preparation of Promoter Deletion Constructs and
Reporter Assay Analysis
PCR. Suitable regions for promoter activity analysis were selected,
based on information obtained from the analysis of the 5RACE results
(Figure 1). Regions upstream of each of the three identified major
transcription start sites were investigated. Each region was amplified
from human genomic DNA (extracted from whole blood using the
Qiagen DNA Blood Mini kit [Qiagen, West Sussex, UK]) using PCR
primers with restriction site consensus sequences for Mlu1 and Xho1
built into the terminal regions of the oligonucleotides. This was neces-
sary to enable subsequent directional cloning into the pGL3E firefly
luciferase reporter vector (Promega Corporation). Tables 2 and 3 give
the oligonucleotide primer sequences and PCR conditions used. All
PCR reactions were performed using 0.5 M of each primer; 0.2 mM
each of dATP, dCTP, dGTP, and dTTP;  0.3 g of genomic DNA;
and 2.6 U of High Fidelity polymerase (Roche Molecular Biochemicals,
Indianapolis, IN). A 5-min hotstart at 95C was followed by a 1-min
denaturation, 1-min annealing, and 2-min extension at 72C. Thirty
PCR cycles were performed per reaction.
Ligation reactions. PCR products were gel purified using Strataprep
minicolumns (Stratagene, La Jolla, CA), and were double-digested with
MluI and XhoI at 37C for 3 to 6 h to produce sticky-ended products.
pGL3E plasmid was treated in the same way. All restriction products
were gel-purified once more and their concentrations were estimated
by electrophoresing on a 1% agarose gel, together with a quantitative
DNA ladder. Ligation reactions were set up using T4 DNA ligase (Pro-
mega Corporation), while maintaining an insert:vector molar ratio of
3:1. Ligations were performed overnight at 4C.
Transformation and cell culturing. Chemically competent DH5
cells were removed from 80C cold storage, and allowed to thaw on
ice for  5 min. Each ligation reaction (5 l) was added to 50 l of
cells, gently mixed, and kept on ice for 20 min. The cell suspensions
were then heat-shocked at 42C for 45 s, after which they were returned
to ice for 2 min. Ampicillin-free LB broth (950 l) was added to each
cell suspension, and the suspensions were incubated at 37C and 150 rpm
for 1.5 h. Each transformant suspension (150 l) was then plated onto
selective ampicillin-containing LB agar plates, and incubated overnight
at 37C. The next day, colonies were picked from each plate and grown
overnight in 5 ml ampicillin-containing LB broths at 37C and 250
rpm. Each broth (5 l) was streaked to a single colony on ampicillin-
containing LB agar plates, and the plates were incubated overnight at
37C. One colony was picked from each plate, and grown in a 5-ml
ampicillin-containing LB broth at 37C and 250 rpm overnight.
Plasmid DNA extraction. Plasmid DNA was extracted from each
E. coli broth using Wizard Plus SV Minipreps DNA Purification System
(Promega Corporation), using sterile deionized water to elute the final
product. An aliquot of each extract was restricted using Mlu1 and Xho1
to excise the insert, and viewed on a 1% agarose gel. Successful plasmids
were submitted for confirmatory sequencing to ascertain that the correct
insert was cloned.
Preparation of plasmids for transfection. Large-scale plasmid prepa-
ration was performed by inoculating 100 ml ampicillin-containing broths
with 100–200 l of broth from a 5-ml culture, and incubating overnight
at 37C with shaking at 250 rpm. Plasmid maxipreps were then prepared
using the Plasmid Maxiprep (Qiagen) purification kit, according to
manufacturer-recommended instructions. At the end of the procedure,
an extra ethanol precipitation step was performed under sterile condi-
tions, to ensure optimum purity and sterility of the plasmid DNA
obtained.
Culturing of mammalian cells. HASM cells and BEAS-2B cells
(ATCC number CRL-9609) were cultured in 75 cm2 flasks until conflu-
ent, using high-glucose Dulbecco’s modified Eagle’s medium containing
10% heat-inactivated bovine calf serum and 4 mM L-glutamine. The
cells were harvested by trypsinization, followed by centrifugation and
resuspension in growth medium. The cell density was adjusted to 105
cells/ml, and 0.5 ml of cell suspension was transferred to each well of
a 24-well tissue culture plate, thus giving a cell count of 5  104 cells/
well. Sufficient tissue culture plates were prepared to allow for transfec-
tions with each different plasmid to be performed in triplicate on the
same plate, together with negative and positive controls. The plates
were incubated at 37C and 5% CO2, until  70–80% confluent.
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Figure 1. Regions of the muscarinic M2
receptor 5UTR amplified for pGL3E
cloning. (*These fragment lengths are the-
oretical and are based on NCBI human
genome data. The actual fragment lengths
for these two constructs were actually
1,550 bp and 1,300 bp due to the presence
of the novel 540-bp region.)
Transfection. Transient transfection was performed using Fugene 6
reagent (Roche Molecular Biochemicals). Each cloned pGL3E firefly
luciferase reporter plasmid was cotransfected with pRL-SV40 (Promega
Corporation), a plasmid expressing renilla luciferase under the influence
of an SV40 promoter. The latter plasmid was used as a transfection
efficiency control. Transfection solutions (100 l) containing 0.75 g
cloned pGL3E DNA, 18.75ng pRL-SV40 DNA (DNA ratio of 40:1) and
2.31 l of Fugene 6 (DNA:Fugene ratio of 3:1), were freshly prepared in
serum-free cell culture medium. Transfection was performed by the
dropwise addition of each tranfection solution to a well containing
growing cells, gentle mixing by swirling, and further incubation at 37C
and 5% CO2 for 48 h. Each plate contained five different plasmid
transfections, a positive transfection control with pGL3C plasmid (Pro-
mega Corporation), a baseline expression control (transfection with
empty pGL3 Enhancer vector) and an untreated control (no transfec-
tion), all performed in triplicate. Four replicates of each 24-well plate
were prepared. The pGL3 Enhancer was used rather than pGL3 Basic
TABLE 2. Oligonucleotide primer sequences used in order to amplify
promoter fragments for subsequent cloning
Primer Sequence
AFPF22 5-CAA TGC GGA AAC GCG TAA TTG CAG ATG GAG
AGC TGG-3
AFPF23 5-CAA TGC GGA AAC GCG TCA TTT GTC AAA GCT
CCA AAG-3
AFPF24 5-CAA TGC GGA AAC GCG TGG AGA TCA CAA ATT
CCC TGA-3
AFPF25 5-CAA TGC GGA AAC GCG TGG ATG AGA GAA AAT
AAA GCC-3
AFPF26 5-CAA TGC GGA AAC GCG TTG CTG TAC TAA AGG
CGC CAG-3
AFPR22 5-TGA ACT TGC ACT CGA GCT GGC GCC TTT AGT
ACA GCA-3
AFPR25 5-TGA ACT TGC ACT CGA GAC CGC TTA GAG TCC
GAG GCC-3
AFPR26 5-TGA ACT TGC ACT CGA GTG TGA CCT GTT CGT
GGT TTA-3
The boxed nucleotides contain the recognition sequence for Mlu1 (forward
primers) (A/CGCGT) or Xho1 (reverse primers) (C/TCGAG). The region 5 of
the recognition sequence consists of a 10-bp noncomplimentary tail, designed
to reduce restriction efficiency problems associated with digestion of terminal
fragments from dsDNA.
plasmid because of the low levels of luciferase activity seen in HASM
cells following transfection with the latter construct.
Dual luciferase reporter assay. Luciferase assays were performed
using the Dual Luciferase Reporter assay system (Promega Corpora-
tion) according to manufacturer’s instructions. The 24-well plates were
removed from the incubator, and the growth medium was aspirated.
The wells were rinsed with phosphate-buffered saline and aspirated.
Passive lysis buffer (100 l) was then added to each well, and the plates
were placed on a rocking platform for 15 min. The lysates were assayed
for firefly luciferase activity by the addition of 20 l lysate to 100 l
of freshly prepared Luficerase Assay Reagent II, and luminescence was
measured in a TD20e (Turner Designs, Sunnyvale, CA) luminometer
programmed to effect a 3-s initial delay followed by a 10-s integration
period. Renilla luciferase activity was assayed by the addition of 100 l
Stop and Glo reagent, rapid vortexing, and luminometric measurement.
Results were normalized for variations in transfection efficiency, by
using the ratio of firefly to renilla luciferase activity as an index of
promoter activity. The promoter activity of each deletion construct was
expressed as fold values over the baseline reporter expression activity
(transfection with empty pGL3E vector).
Determination of potential transcription factor–binding sites. The
online bioinformatics application, MatInspector (10), available at
http://www.genomatix.de/cgi-bin/matinspector/matinspector.pl and the
DNAssist software application (http://www.dnassist.org) were used to
identify transcription factor consensus binding sites in the putative
promoter sequence.
Genotyping. Genotyping of the identified multiallelic (CA)n repeat
was performed by Lark Technologies (Essex, UK) by analysis of PCR
TABLE 3. Primers and annealing temperatures used for amplification of
5UTR regions for pGL3E cloning
PCR for Forward Reverse Annealing
Construct Primer Primer Temperature (C)
A AFPF26 AFPR25 62
B AFPF23 AFPR25 62
C AFPF26 AFPR26 63
D AFPF23 AFPR26 63
E AFPF22 AFPR22 54
F AFPF23 AFPR22 54
G AFPF24 AFPR22 51
H AFPF25 AFPR22 51
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product sizes using an ABI 3,100 genetic analyzer. We generated PCR
products using fluorescently labeled forward primer 5-FAM-5-ATG
GAG AGA AGC GAA AAA GAG C-3 and reverse primer 5-
TTT GGG AGG CAA CAC CTA TTC G-3. Thermal cycling was
performed using an Eppendorf Mastercycler as follows: hotstart 95C
for 5 min, denaturing 94C for 1 min, annealing 64C for 1 min, and
extension 72C for 2 min for a total of 30 cycles. A final extension at
72C for 10 min was performed. A set of 14 control samples consisting
of PCR products generated from plasmids of known genotype (two
separate PCR products for each genotype) was also submitted to Lark
together with the population samples.
Ethical approval. The genomic DNA used in this study was obtained
from an anonymous random DNA bank of Maltese individuals, main-
tained at the Laboratory of Molecular Genetics, Department of Physiol-
ogy and Biochemistry, University of Malta, and from the Outpatient
Asthma Clinic, St. Luke’s Hospital, Guardamangia, Malta. Prior written
ethical approval was obtained from the Research Ethics Committee of
the Faculty of Medicine and Surgery, University of Malta.
Results
5RACE Experiments
At the time of experiment, our 5RACE sequence data aligned
to contig NT_007933.10 in the NCBI human genome database,
as well as partially to AC009332.6 and partially to AC009329.20
found in the general NCBI DNA sequence database.
NT_007933.10 has since been removed and is currently in revi-
sion 12 (NT_007933.12). We have noted a change in the size
of our largest intron when calculated using the most recent
NT_007933.12 data, then when calculated using data from the
superceded contigs.
Analysis of the sequence data arising from both 5RACE
experiments identified the presence of six different mRNA tran-
scripts (Figure 2) and three different transcription start sites
(TSS) for the human muscarinic M2 receptor gene. The second
experiment confirmed the earlier results, and also identified two
new transcripts. We have submitted the sequence data describing
all our identified 5UTR arrangements to GenBank (Accession
nos. AY219704, AY034603, AY034604, AY219705, AY219703,
and AY034605).
The M2 coding sequence is preceded by a 46-bp exon that
is invariably expressed in all mRNA transcripts we obtained.
Upstream of this, we have identified five additional exons of
which exons 5, 4, and 2 are alternatively spliced. The different
Figure 2. Identified arrange-
ments of the human muscarinic
receptor 5UTR. CDS, coding
sequence; TSS, transcription
start site; open boxes, exonic se-
quences; lines, intronic se-
quences. Exonic sizes are shown
in bold and intronic sizes in bold
italic.
upstream arrangments, together with the exon and intron sizes
are shown in Figure 2. Donor and acceptor splice site sequences
were identified at the exon/intron boundaries. This arrangement
suggests the presence of three different transcription start sites,
all of which are active in HASM cells, with the most 5 TSS
(TSS1) lying more than 146 kb upstream from the ATG start
codon of the gene. We have identified a GenBank mRNA se-
quence (Accession no. AL832585.1) submitted by Ansorge and
coworkers (2002) from a cDNA library, which is in perfect agree-
ment with our first 5UTR arrangement in Figure 2.
In the transcripts where Exon 3 was preceded by Exon 2 or
Exon 1, Exon 3 splicing occurred between positions 122,903 and
122,904 in AC009332.6. In transcripts resulting from transcrip-
tion initiation at TSS3, Exon 3 extended by a further upstream
span of 24 nucleotides. We also obtained other transcripts which
initiated within very close proximity of TSS3, and which suggest
that a number of specific TSSs may actually be present around
the region designated as TSS3 (Figure 3).
Our data suggest that the TSS3 region appears to be the
most commonly used transcription start site (8 out of 14 clones),
whereas TSS2 is the rarest (1 out of 14 clones).
Identification of Novel Polymorphic Regions in the Human
Muscarinic M2 Promoter Sequence
During the preparation of the PCR products for cloning into
pGL3E for reporter expression studies, agarose gel analysis
showed that the length of products G and H (Figure 1) was
 500 bp more than expected. Sequencing of this region revealed
a novel 540-bp sequence containing the repeating motif
TC(C)TGG(AC)[AT]n (Figure 4) located between positions
121,646 and 121,647 of AC009332.6. We have submitted this
novel sequence to GenBank (Accession no. AY221504). At the
time of the experiment, this region did not align with any contig
in the NCBI human genome database, although the sequences
flanking it were in perfect agreement with human genome se-
quence data. However, a recently revised NCBI contig
NT_007933.12, dated April 28, 2003 includes sequence data
within this region that is very similar, though not identical, to
ours. Therefore, the real length of regions G and H, used for
cloning in our reporter experiments, is 540 bp more than indi-
cated in Figure 1. Preliminary gel analysis of PCR products
from 22 other human genomic DNA templates obtained from
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Figure 3. NCBI database
sequence showing the posi-
tion of the identified exonic
(shaded) and intronic re-
gions in the 5UTR region
of the human muscarinic M2
receptor gene. The coding
region (CDS) is shown in
uppercase, primer regions
are indicated with a single
underline, and putative
transcription start sites are
indicated with a bold upper-
case letter. at indicates the
bases between which the
hypervariable 0.5-kb region
is inserted, c indicates the
position of the C→A SNP,
double underline indicates
the position of the multial-
lelic (CA) tandem repeat.
The primer and exon names
are denoted by labels on the
right.
different individuals all indicated the presence of this novel
region. Cloning and sequencing of an additional 40 genomic
templates in 8 pools, identified this to be a hypervariable region
of  0.4–0.6 kb, containing a repeating pattern that usually, but
not unequivocally, fits the one described above. The significance
of the polymorphic variation in this novel region is unknown,
although given the functional data presented below, this re-
gion may not contain strong positive elements promoting
transcription.
Sequencing of our plasmids also revealed a novel (CA) tan-
dem repeat region located at 96 bp downstream of TSS1. The
NCBI contig AC009332.6 contains 14 (CA) dinucleotide repeats
in this region. Besides the wild-type alleles, pooled cloning fol-
lowed by sequencing of an additional 40 samples, as described
above, identified alleles with the following deletions (CA)8,
(CA)4, (CA)3, (CA)2, (CA)1, as well as an allele having an
insertion of one (CA) repeat. Genotyping of samples obtained
from an anonymous random DNA bank of Maltese individuals,
maintained at the Laboratory of Molecular Genetics, Depart-
ment of Physiology and Biochemistry, University of Malta,
showed the most common alleles in the white population to be
(CA)1 (44.0%) and wild type (22.3%) (n 	 186) (Table 4).
Repeat PCRs on the same genomic templates yielded a consis-
tent number of (CA) repeats, suggesting that these are real
alleles and not the result of PCR artifacts such as slippage.
We have also identified a common C→A SNP located at
position 122,159 on NCBI AC009332.6 (136 bp upstream from
the most 5 TSS). Our preliminary data suggest that the allelic
frequency of the A allele is 52% (n	 80) in the white population.
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Figure 4. Novel sequence located between positions
121,646*and 121,647**of AC009332.6. Bases in ital-
ics denote the novel sequence, whereas bases in nor-
mal text denote regions which agree with the NCBI
human genome sequence database information.
Bold bases indicate the starts of the repeating motif
TC(C)TGG(AC)[AT]n (curved brackets denote
bases that may or may not be present).
Dual Luciferase Reporter Gene Experiments
To investigate the potential promoter activity contained in
regions upstream of the identified transcription start sites 1 to
3, a reporter gene approach was used. We transfected primary
HASM cells and the human bronchial epithelial cell line BEAS-
2B to look for airway tissue selective expression. Luciferase
gene-based reporter assays were performed as previously de-
scribed (12).
Reporter assay data showed that the highest promoter activity
is present in the DNA regions upstream from TSS3 for both
HASM and BEAS-2B cell transfectants, whereas low activities
were obtained for regions upstream of TSS1 (Figures 5 and 6).
HASM cell transfectants expressed lower luciferase activities
than BEAS-2B, and also showed higher SEM values than BEAS-
2B cells. This trend has been observed with several other trans-
fection experiments from our group (12), and is likely to be due
to the inherent variability in transfection of human primary cell
culture systems.
The results obtained from HASM transfectants for activities
upstream of TSS3 showed construct A to have higher activity
than B (32.2 
 3.3 versus 18.9 
 3.5 fold over empty vector
[mean 
 SEM], P  0.05, n 	 4). With respect to the region
upstream of TSS2, construct C showed a trend toward higher
activity than D (5.0
 1.6 versus 3.4
 0.3 fold over empty vector
[mean 
 SEM], n 	 4), although the differences did not attain
statistical significance (Figure 5). These data suggest that the
sequence upstream of TSS1 might contain elements which act
as repressors in HASM cells. This might also explain the low
activities observed for regions E, F, G, and H, upstream of TSS1.
This pattern was reversed in BEAS-2B cell transfectants (Fig-
ure 6). Construct B showed higher activity than A (57.4 
 4.1
versus 34.2 
 1.3 fold over empty vector, n 	 4, P  0.01) and
D showed higher activity than C (31.9 
 2.0 versus 14.3 
 0.9
fold over empty vector, n 	 4, P  0.001), suggesting that such
TABLE 4. Allelic frequencies of muscarinic M2 promoter (CA)n variants
in the random white population (n  186)
Number of (CA) Allelic frequency
Allele repeats present (% )
Insertion (CA)1 15 0.6
Wild-type 14 22.3
(CA)1 13 44.0
(CA)2 12 0.6
(CA)3 11 14.9
(CA)4 10 0.6
(CA)8 6 17.1
postulated repressor elements may be cell type–specific, and may
not operate in BEAS-2B cells.
We also investigated the potential role of the novel (CA)
tandem repeat on reporter gene expression in these systems.
Construct A containing the wild-type allele, produced a signifi-
cantly higher reporter expression than the (CA)8 construct A,
in both HASM cell transfectants (32.2 
 3.3 versus 13.8 
 5.4,
n 	 4, P  0.05) (Figure 5B) and BEAS-2B cell transfectants
(34.2 
 1.3 versus 20.6 
 3.3, n 	 4, P  0.01) (Figure 6B).
Determination of Potential Transcription Factor Binding Sites
Using MatInspector (13) and DNAssist, the potential promoter
sequence was searched for transcription factor consensus bind-
ing sites. The selected results of this are shown in the online
supplement.
Discussion
Muscarinic M2 receptors play an important role in the regulation
of adenyl cyclase activity in HASM. In this article we describe
the genomic organization of the human muscarinic M2 receptor
gene 5UTR, and suggest regions of major transcriptional regula-
tory activity relevant for control of M2 receptor expression in
ASM.
The results of this work are based on two 5RACE experi-
ments performed on two separate occasions using different pop-
ulations of HASM cells. The 5RACE protocol adopted here
includes some modifications over standard 5RACE procedures.
In brief, it eliminates the participation of uncapped or truncated
mRNA transcripts in the 5RACE reaction, by prior CIP dephos-
phorylation of the 5 ends, thus reducing the possibility of 5
ends of incomplete transcripts being falsely identified as TSSs.
This approach has also been successfully used by other research
groups (14–17).
In initial experiments, we also used a primer extension analysis
approach, but found this to result in unreliable amplification for
the 5UTR of this gene. In this respect, other researchers have
reported problems with primer extension analysis for a number
of GPCR genes, and this has been ascribed to the presence of
GC-rich sequences within the 5 noncoding regions (7, 18).
We identified three regions of transcription initiation in the
human muscarinic M2 receptor gene 5UTR, with each region
containing a cluster of specific transcription start sites (TSSs) in
close proximity to each other. The region also contains five exons
of which Exon 2, Exon 4, and Exon 5 are alternatively spliced
(Figure 2). The most 5 TSS lies more than 146 kb upstream
from the ATG start codon of the gene. An NCBI GenBank
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Figure 5. Luciferase re-
porter activity for HASM
cell transfectants. Data
are expressed as fold
values over empty vec-
tor baseline control. (A )
Luciferase activity re-
sults of all deletion con-
structs. (B ) Luciferase
activity results of the
(CA)8 and wild-type
alleles of construct A.
The error bars denote
the SEM (*P  0.05).
mRNA sequence (Accession no. AL832585.1), submitted by An-
sorge and coworkers (2002) from a cDNA library, is in perfect
agreement with the first 5UTR arrangement shown in Figure
2. Further evidence of the existence of these arrangements arises
from the presence of donor/acceptor splice sites at each exon/
intron boundary.
Reporter gene expression analysis performed on primary cul-
tures of HASM cells, transiently transfected with pGL3 En-
hancer constructs, provided data which strongly suggest that the
major regulatory region lies immediately upstream of TSS3. In
view of this, it is interesting to note that transcription initiation
region 3 also contains the majority of clustered TSSs and the
highest frequency of mRNA transcripts appears to originate
at TSS3 in primary HASM cell cultures. Moreover, from the
differences in expression between construct A and B (Figure 5),
it appears that repressor elements may operate upstream of
TSS1. The decreased expression of construct D compared with
C adds weight to this argument. All constructs containing regions
upstream of TSS1 showed low levels of expression, and there
may potentially be some repressor elements operating at the 5
Figure 6. Luciferase re-
porter activity for
BEAS-2B cell trans-
fectants. Data are ex-
pressed as fold values
over empty vector base-
line control. (A ) Lucif-
erase activity results of
all deletion constructs.
(B ) Luciferase activity
results of the (CA)8
and wild-type alleles of
construct A. The error
bars denote the SEM
(**P  0.01, ***P 
0.001).
end region of H, considering that this construct showed lower
expression levels than G.
The reporter assay results obtained for the BEAS-2B assay
data also indicate the highest levels of positive transcriptional
regulatory control to be present directly upstream of TSS3. How-
ever, in this cell type, the postulated repressor elements de-
scribed above do not appear to exert an effect. Indeed construct
B exerted higher positive transcriptional regulation than A and
construct D exerted higher positive transcriptional regulatory
control than C. In addition, construct H also showed higher
promoter activity than G, as opposed to HASM cells, suggesting
that any transcriptional repressor elements present in the 5
terminal region of H may operate in HASM cells but not in
BEAS-2B.
These observations may be partially explained by the differ-
ent transcription factor pool compositions expected to be present
in different cell types. Although HASM cells express the M2
receptor on the cell membrane, both in cell culture and in whole
animal models, there is no current evidence to support the ex-
pression of M2 receptors in BEAS-2B human airway epithelial
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cells. Different reporter expression profiles may be expected to
be observed in further cell types.
This work has identified polymorphic variation within the
promoter region of the muscarinic M2 receptor gene. A (CA)
tandem repeat polymorphism present downstream of TSS1 has
been shown to significantly alter reporter gene expression in
HASM and BEAS-2B cell transfectants, and may therefore po-
tentially affect muscarinic M2 receptor expression in HASM cells
in vivo. The 0.5-kb hypervariable region is present in a region
of low promoter activity, and is therefore not expected to offer
a significant contribution to the overall level of M2 receptor
expression in HASM cells, whereas the identified C→A SNP is
of unknown relevance.
A map of transcription factor consensus sequences within the
postulated regulatory regions is presented in the online supple-
ment. In line with all muscarinic receptor promoters currently
identified, the human muscarinic M2 receptor promoter is
TATA-less. Sp1, AP, and GATA transcription factors have pre-
viously been cited as relevant for TATA-less promoters (5, 7,
10, 19, 20). In view of this it is interesting to note that the highest
incidence of Sp1, GATA, and AP sites lies within the region of
maximum transcriptional regulatory activity, immediately up-
stream of TSS3. It is also interesting to note a cAMP receptor
element–binding protein (CREB) consensus binding sequence
present upstream of TSS2. cAMP activates the kinase PKA,
which in turn phosphorylates CREB’s activating region, increas-
ing the affinity of CREB for CREB-binding protein (CBP). CBP
is believed to interact with one or more parts of the transcrip-
tional machinery, exerting a positive transcriptional regulatory
effect. Therefore, cAMP may potentially influence M2 transcrip-
tional regulatory control.
One particularly striking aspect of the work reported here is
the high homology between the human and porcine 5UTR
sequences: there is 77–86% homology between the porcine Exon
1B and significant sections of the human Exons 1 and 3. In
addition to the exon homology, there is also a small but signifi-
cantly homologous portion in the putative promoter where 32
bp match the published chick promoter region (GenBank Acces-
sion no: U61850) by 91%. Indeed, this significant homology has
also been noted in the 5 arrangements of other muscarinic
receptor subtypes: one of the five exons upstream of the M3
receptor coding sequence is homologous to the reported bovine
M3 receptor cDNA (8), and the 5 exon in the rat M1 receptor
5UTR shares significant homology with the 5 end of porcine M1
receptor cDNA (5, 21). Despite the observation that muscarinic
receptor subtypes sharing common pharmacologic properties
also share common structural features due to sections of coding
sequence homology, there was no significant homology between
the M2 receptor upstream arrangement described in this paper
and the rat M4 receptor promoter region or exon 1 (GenBank
Accession no: D78484.1) as analyzed using BLAST (http://
www.ncbi.nlm.nih.gov/blast).
In addition to the nucleotide similarity between species, there
appears to be a conserved pattern of exon organization between
species and also between the muscarinic subtypes. A consensus
splice acceptor point is observed 47 bp upstream of the ATG
start codon in the human M2 receptor gene, as confirmed in this
paper and recognized by Bonner and colleagues (3), and this is
largely replicated in the porcine M2 (46 bp) (4), the chick M2
(41 bp) (6), the rat M1 (69 bp) (5), the rat M3 (20 bp) (3),
the rat M4 (32 bp) (19), and the human and rat M5 (78 bp)
(22).
Alternative splicing was observed to occur for the human
muscarinic M2 receptor, as shown in Figure 2, as well as for the
porcine M2 receptor. The porcine M2 receptor gene is reported
to have two upstream exons, 1A and 1B, with exon 1B being
alternatively spliced (4). The 5 exons of human muscarinic M3
receptor subtype have also been reported to be alternatively
spliced (8), as have the rat M1 and M4 receptor genes. Not only
do all these genes exhibit alternative splicing, but they also all
include relatively large introns separating their single coding
regions from upstream noncoding exons. We were particularly
surprised by the size of the intron between exons 2 and 3 of the
M2 5UTR. It seems probable that it is the size of these introns
and the complex upstream arrangement of these genes which
has confounded their identification since the coding sequence
was published in 1987 (3, 22).
All muscarinic receptor gene promoters found to date are
TATA-less and generally have numerous transcription factor
binding sites with Sp1, AP, and GATA being cited as relevant
(5, 7, 10, 19, 20). These characteristics appear to be typical of
promoters for housekeeping genes, which are constitutively
expressed. However, recently a number of investigations have
reported some highly regulated genes to have TATA-less promot-
ers (23). GPCRs observed to have GC-rich, TATA-less promoters
include D1, D2, and D5 dopaminergic and the 1 adrenergic recep-
tor (18, 24–27). All of these promoters have also been observed
to contain Sp1 sites, although the transcriptional requirement
of Sp1 has not been demonstrated. However, Sp1 binding has
been shown to be a critical requirement for transcription initia-
tion in the TATA-less promoters of some genes (28, 29). The
only investigation to date into the relative control by transcrip-
tion factors over M2 receptor regulation has shown the GATA
family to be of importance: the expression of a construct con-
taining the chick M2 promoter was observed to be critically
dependent on the GATA-responsive element in cardiac primary
cultures (20).
Although in this study we have defined the transcription start
sites important for transcriptional control of the M2 receptor in
ASM, this receptor is also important in other cell types, such as
cholinergic nerves. Transcripts derived from different cells may
exhibit different upstream arrangements. Rosoff and coworkers
(6) observed the chick M2 promoter to have five transcription
start sites, some of which were used equally in both chick heart
and brain but some were expressed preferentially in one of the
tissues. Zhou and coworkers (9) recently described a muscarinic
M2 promoter arrangement based on work performed on mRNA
transcripts obtained from human heart muscle and the human
neuroblastoma cell line IMR-32 (ATCC no. CCL-127). Their
work identified a single TSS that was present 55 bp upstream
of the 22.6-kb intron, specifically at position 61,715,148 of
NT_007933.12 or position 58,329 of AC009329.20. This corre-
sponds to a location located within the Exon 5 reported in this
article. These data, together with the data presented in this
paper, suggest that tissue-specific regulation of M2 receptor
transcription may be an important mechanism controlling
expression.
Analysis of promoter activity in our cell culture systems sug-
gests that the most important 5 regulatory area for the M2
receptor lies upstream of TSS3, with the presence of a multiallelic
tandem CA repeat in this region potentially contributing to
variations in activity. Although it is currently unclear how this
tandem repeat actually exerts its influence, it may be postulated
to affect the expression of muscarinic M2 receptors in airway
tissue. Such an alteration in expression might be expected to
contribute to the interpatient variability in airway hyperrespon-
siveness observed in patients with asthma and in patients with
COPD. In inflammatory conditions of the airways, there is an
elevated degree of airway hyperresponsiveness that is due to
both inflammatory and neurogenic factors, and that also poten-
tially includes a degree of M2 receptor dysfunction induced by
allosteric modulation by EPO and MBP (30, 31) as well as in-
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creased downregulation induced by tumor necrosis factor- and
interleukin-1 (32). The CA repeat we report here has the poten-
tial to alter levels of M2 receptor expression, which provides an
additional mechanism controlling functional effects driven by
M2 receptor stimulation. Such effects include short-term inhibi-
tion of adenylate cyclase (1) as well as long-term sensitization
of adenylate cyclase following chronic stimulation or modulation
by interleukin-1 or rhinovirus (33).
In summary, we have characterized the 5UTR of the human
muscarinic M2 receptor gene and have identified the major tran-
scriptional regulatory regions for this gene in HASM. In common
with other muscarinic receptors, the promoter contains multiple
exons, some of which are alternately spliced, and contains multi-
ple transcriptional start sites. The region of major transcriptional
activity is located more than 146 kb upstream from the gene
coding region. We have also identified a novel hypervariable
region (which is, however, located in a region of low promoter
activity), a multiallelic CA tandem repeat region which alters
transcriptional activity in reporter assays, and a biallelic C→A
SNP, the relevance of which remains to be determined. Taken
together, these data suggest that genetic variability may produce
inter individual differences in the control of airway M2 receptor
expression.
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